National Academies Press: OpenBook

Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop (2022)

Chapter: 4 Advancing Clinical Development: Challenges and Opportunities

« Previous: 3 Mechanisms of Action and Key Research Gaps for Psychedelics and Entactogens
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×

4

Advancing Clinical Development: Challenges and Opportunities

Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×

The novelty of psychedelics and entactogens for treating psychiatric disorders paired with marked psychoactive effects of these drugs presents unique challenges to evaluations of efficacy and will require modifications to standard clinical trial design, said Gerard Sanacora, Gross Professor of Psychiatry at the Yale University School of Medicine, Director of the Yale Depression Research Program, and Co-Director of the Interventional Psychiatry Program at Yale-New Haven Hospital. Indeed, the high degree of enthusiasm and anticipation for psychedelics is “beyond anything we have ever seen with any unapproved psychiatric drug,” said Javier Muñiz, Commander in the U.S. Public Health Service and associate director for Therapeutic Review in the Division of Psychiatry, Office of New Drugs at the Food and Drug Administration (FDA).

Muñiz noted that although hundreds of papers were published between the 1960s and 1990s on the use of psychedelics, most had methodologic problems that would not meet today’s rigorous regulatory standards. In

Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×

the past 20, however, he said there has been a resurgence in high-quality research, as illustrated in Figure 4-1. Within FDA, Investigational New Drug Applications (NDAs) have also surged in the past few years, said Muñiz. However, he noted that in an evidence-based summary of literature on the clinical application of psychedelic drugs in psychiatric disorders, Reiff and colleagues concluded that while randomized controlled trials support the efficacy of 3,4-Methylenedioxymethamphetamine (MDMA) for the treatment of posttraumatic stress disorder (PTSD) and psilocybin for the treatment of depression and cancer-related anxiety, the data are currently insufficient for FDA approval of these drugs for routine clinical use (Reiff et al., 2020).

When FDA reviews an NDA, they look for evidence of both safety and efficacy, said Muñiz. Features of FDA’s existing regulatory framework that are most relevant to psychedelic drugs include the requirement that a study permits a valid comparison, that bias on the part of both participants and observers is minimized, and that the methods of assessment are well defined and reliable, he said.

CONFOUNDERS TO EFFICACY ASSESSMENTS

Muñiz mentioned several factors associated with psychedelics that confound efficacy assessment. For example, psychedelic treatment is provided by highly engaged therapists and monitors, which in and of itself may be therapeutic, as mentioned earlier. In addition, Muñiz noted that both patients and therapists often have elevated expectations about efficacy, fueled in part by highly favorable media coverage; elaborate intervention protocols may further increase the placebo response. There are also issues related to blinding because the dramatic responses some people experi-

Image
FIGURE 4-1 Psychedelic scientific publications by year. The number of psychedelic publications has increased substantially in the past 20 years, according to the web of science publication count.
SOURCES: Presented by Javier Muñiz, March 30, 2022; Petranker et al., 2020.
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×

ence when taking psychedelics may result in what is known as functional unblinding, said Muñiz. Finally, he noted that psychedelics appear to have unique suggestibility properties, which can complicate the reliability of participant reporting.

Muñiz highlighted three challenges that merit further consideration from a regulatory perspective: (1) the inclusion of psychotherapy as a treatment element, (2) the importance of set and setting, and (3) the challenge of making valid comparisons and minimizing biases.

Psychotherapy as a Treatment Element

Psychotherapy is integral to maximizing the treatment effect and ensuring safety, said Muñiz, but it has not been rigorously defined and standardized for use during psychedelic treatment. It is typically involved at three stages of psychedelic trials—at the preparatory stage to help build rapport and establish goals and intentions; during the in-drug treatment sessions to facilitate the sessions and reduce adverse psychological reactions; and in the weeks and months following the administration of psychedelics to process and integrate the experience and ensure psychological stability. “However, we don’t know which features of the psychotherapy intervention are critical for efficacy or what minimum components of the psychotherapeutic intervention are necessary to ensure safety,” said Muñiz, adding that this information is critical for labeling. For example, Sanacora mentioned that if psychedelics are inducing long-term plasticity in humans similar to what the preclinical studies show, it might be better to implement psychotherapeutic augmentation strategies after giving participants a chance to recover from the treatment.

To fully tease out the safety and efficacy contributions of psychotherapy would require well-done factorial studies, said Muñiz. He noted, however, that while FDA regulates labeling, it does not regulate the practice of medicine, which includes off-label prescribing and psychotherapy. They have, however, written labels specifying that a drug should be used only in conjunction with another mode of therapy, said Muñiz. For example, the label for naltrexone as a treatment for alcohol and opioid dependence states that the drug should be part of a “comprehensive management program that includes psychological support.” Another approach FDA uses to ensure safe use of a drug is by requiring a risk evaluation and mitigation strategy1 that could include elements such as provider training or certification, said Muñiz, noting that this requirement must not be unduly burdensome to patients or the health care system. He added that while risk evaluation and mitigation strategy (REMS) is usually proposed by a sponsor, FDA is con-

___________________

1 21 U.S. Code Section 355-1.

Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×

sidering developing a REMS program for psychedelics given the complexity of the risks associated with these agents.

Steven Levine, senior vice president of patient access and medical affairs at COMPASS Pathways, noted that the model of psychological support used in psychedelic therapy was designed not to provide psychotherapy per se, but to accompany, facilitate, and ensure safety within trials. Video recordings are also used to ensure patient safety, including with regard to the patient–therapist relationship, added Levine. Corine de Boer, chief medical officer of Multidisciplinary Association for Psychedelic Studies (MAPS) Public Benefit Corporation (PBC), agreed that therapists are important for both safety and efficacy, and with the long duration of treatment sessions, two therapists are essential for practicality and safety. “During psychotherapy outside of the psychedelic world, there is always a power relationship between the therapist and the patient, and psychedelics are no different,” she said. Psychedelics may introduce additional risk by creating more openness and more trust, de Boer said.

In addition, the potential for sexual misconduct during treatment sessions has long been a concern to FDA, said Muñiz, in part because of media exposure from specific cases. However, he said this aspect of safety might be beyond the scope of FDA’s authority. The agency is working closely with sponsors to discuss specifics about monitoring, video recording, who is in the room, and what degrees and experience the therapists must possess, he said. How this will translate in the real world in terms of cost-effectiveness and delivery burden if these drugs are approved is unknown, said Muñiz.

Set and Setting

Set and setting are considered integral to a positive psychedelic treatment effect, said Muñiz. The regulatory challenges, he said, are (1) identifying the minimum parameters required to ensure safety, and (2) communicating these requirements on the label. He added that the agency is also working with sponsors to protect patients in clinical trials from the “unique risks that may be associated with the nature of these treatments, including sexual misconduct.”

Guides or “sitters” are key to ensuring a therapeutic set and setting, yet there are few data to characterize different approaches that sitters may take, said Srinivas Rao, chief scientific officer and co-founder of atai Life Sciences. For example, while many practitioners emphasize the need for a music playlist and eyeshades, he questioned whether there are data to support those elements. He added that the role of sitters is complex and extends beyond the psychedelic experience, reiterating the need for prep work, expectation setting, and support.

Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×

Concerns about scaling and standardizing the training and actions of sitters motivated Rao and colleagues to explore digital approaches to standardize therapy. Virtual reality systems could be especially helpful, he said, for example, by enabling the detection of incipient anxiety and modulating it. He suggested that visual stimulation or changing the music might help modulate safety and/or efficacy.

Rao’s company is also exploring much shorter acting compounds that could substantially alter the role, or even the need, for a sitter. “Digital may be particularly well suited for some of these compounds,” he said.

Minimizing Bias

Sponsors and regulators have also considered various approaches to enable making valid comparisons, minimizing bias, and accounting for the “dramatic functional unblinding,” said Muñiz. For psychedelic drug development, the use of traditional placebo controls has significant problems, he said.

Placebo effects, or changes in the neurobiological underpinnings of a clinical outcome, result from positive expectations, prior experience, and other aspects of the therapeutic encounter, such as the patient’s mindset, and the psychosocial setting, said Luana Colloca, professor of pain and translational symptom science at the University of Maryland, Baltimore, and an expert in placebo mechanisms. Conditioning can also contribute to the placebo phenomenon, and some people are stronger placebo responders than others (Colloca and Barsky, 2020; Colloca and Miller, 2011). Sanacora added that non-specific effects, or placebo effects, are not unique to psychedelic treatments, but they contribute to a large portion of the effects of most central nervous system treatments.

Some of the strategies researchers have employed include using active controls, subperceptual doses of psychedelics as controls, blinding questionnaires, and raters blinded to the treatment allocation, said Muñiz, noting that each of these approaches has limitations. For example, it may be difficult to identify an active control that has similar subjective effects but is not therapeutic, he said. Low doses of psychedelics may still have psychoactive properties, potentially reducing statistical power and increasing the likelihood of false-negative results. Colloca added that expectations should be measured in both patients and health care providers, and that conditioning can be used to manage placebo effects.

Acknowledging how difficult it is to minimize functional unblinding, Muñiz proposed conducting pivotal dose-response trials without a placebo control, which is explicitly allowed by the Code of Federal Regulations, Title 21, Section 314 and has been addressed in a guidance document from FDA (2003). He said that an NDA could conceivably include just two of

Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×

these trials but recommended that at least one include a placebo arm for safety characterization.

Additional challenges mentioned by Muñiz include the poorly understood dose-response relationship of psychedelics (Sellers et al., 2018), the generalizability of the treatment given the highly selective patient population enrolled in current studies, the need to understand parameters for retreatment, the need for a non-clinical safety database, and the need for formal studies of abuse potential (Calderon et al., 2018; Sellers et al., 2018). Colloca noted the need for much larger trials than have been conducted thus far, as well as replication studies and data-sharing consortia.

The Role of the Conscious Experience

One remaining unanswered question regarding the critical elements in psychedelic trials is how much the conscious experience has to do with the enduring effects of these drugs, said Sanacora. Charles Raison, the Mary Sue and Mike Shannon Distinguished Chair for Healthy Minds, Children, and Families at the University of Wisconsin–Madison, took the question one step further, asking whether it might be possible to modulate the therapeutic benefit by tweaking the state of consciousness of patients during their psychedelic treatment session.

In Chapter 3, David Olson discussed the development of non-psychedelic psychoplastogens—drugs that have been engineered to remove hallucinogenic-causing properties. If these agents prove to retain therapeutic effects, the implication would be that the conscious psychedelic experience is not necessary, said Raison. Similarly, if people were sedated before taking psychedelics and still experienced relief from their psychiatric symptoms, or even if 1 week or so later they said, “I can’t tell you why, but I feel like a different person. I want to live my life differently. I look at the world differently,” this too would suggest that the conscious experience is not necessary, said Raison. Blinding trial participants would likely be relatively simple, and such a drug would have enormous commercial appeal, he said. He cautioned, however, that anesthetics might disrupt whatever brain effects were linked to psychedelics and also have antidepressant effects.

Raison suggested that doing those kinds of studies is, from a scientific perspective, one of the most important steps the field needs to take. Moreover, he said that if indeed the conscious experience is not importantly causal, “I think the field has a mandate to figure out what is the least amount of psychosocial support [in which] these agents can be safely administered.” Needing less support would improve the cost effectiveness of these treatments and make them easier to scale and standardize, he said.

However, if consciousness is a key player and the narratives that come out of it are driving benefits in some real way, it immediately raises ques-

Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×

tions about how to optimize the treatment in terms of the depth and longevity of the response, and fully blinding a study would be “more or less logically impossible,” said Raison. “We know that unexpected, untoward conscious experiences can produce long-term changes in mental functioning—posttraumatic stress being a classic example of that,” he said. “So we would expect to see differential lengths of benefit and hence, differential needs for re-dosing depending on whether or not the conscious experience has causal power or whether it’s really more of these basic synaptogenic-type mechanisms.”

Raison added that even if the conscious experience is not essential for therapeutic benefits, there might be other potential benefits. He cited a recent 12-month follow-up study of 27 patients treated with psilocybin for moderate to severe depression, in which mystical experiences correlated with increased well-being but did not correlate with persistent antidepressant effects (Gukasyan et al., 2022). “This is an interesting complexity,” he said. “Maybe the conscious narrative elements are more impactful on certain relevant metrics than on others.” He added that if the conscious experience is not driving efficacy, more frequent re-dosing may be necessary, and relatively similar benefits might be seen both in people who have treatment resistance and in those who are earlier in their disease course. However, if narrative consciousness elements do play a key role, these agents would likely be more impactful early in the disease course or on a recurrent basis in people with treatment-resistant depression, he said.

Sanacora suggested that it is unrealistic to think that the conscious effects are unrelated. “The much harder question is how they are related,” he said, and whether other elements that influence the conscious experience, such as set and setting, would need to be optimized individually for each person.

CLINICAL EFFICACY: RECENT TRIALS WITH MDMA AND PSILOCYBIN

Despite the challenges of conducting clinical trials of psychedelics and entactogens, several have been completed or are under way.

MDMA-Assisted Therapy Trials for PTSD

Between 2014 and 2017, MAPS conducted six randomized, double-blind Phase 2 clinical trials of MDMA for the treatment of PTSD, which were reported in a pooled analysis by Mithoefer and colleagues (2019). Collin Reiff, assistant professor of psychiatry at the New York University Grossman School of Medicine, summarized the data from the 105 participants in those trials, who had a mean duration of PTSD of 215.3 months.

Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×

Most participants (86.8 percent) had a lifetime history of suicidal ideation and 30.9 percent had a history of suicidal behavior, said Reiff. Prior to starting treatment, there were three non-drug, 90-minute therapy sessions, he said. Approximately two-thirds of the participants received MDMA at doses between 75 and 125 milligrams, while about one-third received a placebo/control dose of 0 to 40 milligrams of MDMA, coupled with manualized psychotherapy in 2- to 3-hour sessions about 1 month apart, said Reiff. Study participants also had three 90-minute, non-drug therapy sessions prior to the first MDMA session, and three to four additional non-drug therapy sessions following each treatment session.

The primary outcome measure was change in total score on the Clinician-Administered PTSD Scale for DSM-IV2 (CAPS-IV), which was administered at baseline and at follow-up visits. After two blinded experimental sessions, the active group had significantly greater reductions in the CAPS-IV total scores from baseline than the control group, with a Cohen’s D effect size of 0.8, which indicates a large treatment effect, said Reiff. Also after two sessions, 54.2 percent of participants in the active group no longer met the DSM-IV PTSD diagnostic criteria compared with 22.6 percent in the control group. Dropout rates were much lower than the average dropout rate for clinical trials, said Reiff.

These Phase 2 trials led to a Phase 3 trial that included 90 adults with chronic PTSD across 15 clinical sites (Mitchell et al., 2021). A CAPS updated with the DSM-5 criteria was used in this trial (CAPS-V), said Reiff. Participants were tapered off their existing medication prior to the study and participated in three preparatory sessions with a male/female therapeutic dyad, followed by an experimental session with MDMA or placebo, and three integration sessions. Each participant received MDMA three times, followed by a set of three integration sessions. In this study, overall scores in CAPS-V dropped nearly 25 points in the MDMA plus psychotherapy group compared with 14 points in the placebo plus psychotherapy group, said Reiff. He added that the MDMA plus psychotherapy group had double the reduction in severity of their PTSD symptoms compared with the placebo group and an effect size of 0.9, “suggesting a large and meaningful difference for MDMA-assisted psychotherapy,” said Reiff. As a comparison, he said selective serotonin reuptake inhibitors (SSRIs) approved for the treatment of PTSD have effect sizes between 0.3 and 0.5 in clinical studies.

___________________

2 The Diagnostic and Statistical Manual of Mental Disorders (DSM) “is the handbook used by health care professionals in the United States and much of the world as the authoritative guide to the diagnosis of mental disorders.” The DSM-IV and DSM-5 are earlier editions of the handbook; the DSM-5-TR is the current edition. For more information about the DSM, see https://psychiatry.org/psychiatrists/practice/dsm/frequently-asked-questions (accessed June 12, 2022).

Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×

Figure 4-2 graphically illustrates the results of this trial. “The difference for remission is staggering,” said Reiff. About 30 percent of participants taking MDMA achieved remission compared with only about 5 percent in the placebo group. He added that MDMA did not induce adverse events of abuse potential, suicidality, or QT c prolongation, a heart condition that can be induced by some drugs.

In 2018, Jerome and colleagues at the MAPS PBC published the results of a pooled analysis of six Phase 2 trials of MDMA-assisted psychotherapy for the treatment of PTSD. The results showed that after two to three active doses of MDMA, there was a reduction in PTSD symptoms within 1 to 2 months of treatment completion and increasing symptom improve-

Image
FIGURE 4-2 Treatment response in a Phase 3 trial of MDMA-assisted therapy for PTSD. Response and remission rates as a percentage of total participants randomized to MDMA (red) versus placebo (blue) after each of three treatment sessions. Responders defined as ≥ 10-point decrease in CAPS-V score. Loss of diagnosis defined by specific diagnostic measure on CAPS-V. Remission defined as loss of diagnosis plus a total CAPS-V score of ≤ 11. Non-response defined as a ≤ 10-point decrease on CAPS-V.
NOTE: MDMA = 3,4-methylenedioxymethamphetamine; PTSD = posttraumatic stress disorder.
SOURCES: Presented by Collin Reiff, March 30, 2022; Mitchell et al., 2021.
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×

ment for 12 months (Jerome et al., 2020). The percentage of patients who no longer met PTSD criteria increased by 56 percent at treatment exit to 67 percent at the 12-month follow-up session, according to de Boer. Yet, she noted that MDMA did not work for all participants. Despite having data from 375 patients who were exposed to MDMA in these trials, de Boer said they have not been able to identify prognostic indicators of who will respond to this treatment. “I think this is critical both for the field and for patients and participants,” she said. de Boer added that while MDMA is given three times over the course of 4 months, other antidepressants are often given for weeks, months, or years, only to have symptoms return when the medication is stopped.

On the basis of these results, a Phase 3 study was conducted comparing 46 participants who received MDMA to 44 who received the placebo. At the end of the study period, placebo participants were invited to cross over. Long-term data are still being collected, said de Boer. Colloca noted that outcomes observed in crossover designs can be altered by conditioning responses due to prior therapeutic experiences. Response to both placebos and active drugs can be affected by conditioning and learning effects, she said.

In addition to not working for all participants, de Boer said this treatment has clear risks. The Phase 2 study showed that low-dose MDMA does not provide symptom relief and can cause anxiety, she said. Therefore, they used an inactive placebo in the Phase 3 trial. Participants on SSRIs also needed to be tapered off those medications before they could receive MDMA.

de Boer added that increasing diversity among participants and therapists in clinical trials is important. “As we all know, in clinical trials, marginalized communities are underrepresented.” Part of the MAPS PBC mission is to make sure these modalities will become available for these communities, she said.

Psilocybin Trials for Depression

Several studies have been reported of the successful use of psilocybin for the treatment of depression and treatment-resistant depression, according to Reiff. In an open-label feasibility trial, 12 participants received two oral doses (10 mg and 25 mg) of psilocybin 7 days apart in a supportive setting, with psychological support provided before, during, and after each session (Carhart-Harris et al., 2016). Depressive symptoms were substantially reduced at week one and at follow-up 3 months later, he said.

This study led to a Phase 2 double-blind, randomized controlled trial comparing psilocybin to the SSRI escitalopram, said Reiff. Patients in the psilocybin group received two doses of 25 milligrams 3 weeks apart, plus 6 weeks of daily placebo (akin to taking escitalopram), while those in the

Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×

escitalopram group received a 1 milligram dose of psilocybin (control) 3 weeks apart plus 6 weeks of daily oral escitalopram (Carhart-Harris et al., 2021). While this study did not show a significant difference in antidepressant effects between psilocybin and escitalopram, Reiff said secondary outcomes “generally favored psilocybin over escitalopram.”

In 2019, COMPASS Pathways launched the Phase 2b COMP360 trial to assess the safety, efficacy, and appropriate dosing of psilocybin in participants with treatment-resistant depression. Levine recapped the design and key elements of the trial, in which 233 participants at more than 20 sites in 10 countries received a single dose of an oral synthetic GMP (Good Manufacturing Practice)-grade formulation of psilocybin. Following preparatory sessions, the treatment was given at one of three doses (1, 10, 25 milligrams) with psychological support from a trained therapist in a standardized, controlled therapeutic setting; integration sessions followed, said Levine. The primary outcome was changed in the Montgomery-Åsperg Depression Rating Scale (MADRS) from baseline to 3 weeks, he said.

Nearly all participants (94 percent) had no prior experience with psychedelics before the trial, said Levine. Two-thirds had a history of suicidal thinking or behavior, although candidates with active suicidality were excluded from the trial, he said. He added that participants were withdrawn from other antidepressants before the trial.

Although the results of this study have not been peer reviewed and published, Reiff reported top-line findings that were disseminated by the company through press releases. These reports indicate that the study achieved its primary endpoint with a 25-milligram dose, demonstrating a significant reduction in MADRS score compared with the 1-milligram dose at 1, 3, and 6 weeks after drug administration.

Although the trial used a psychological support model that provided the minimum components of therapy necessary, robust responses were seen with a dose-response relationship, said Levine. A durable effect was seen in a subset of participants, and investigations are under way to understand who responded and who did not, he said.

“This trial is the largest to date and provides a response rate at about one-half of those observed in prior open-label and randomized clinical trials,” said Reiff. “This is probably the most explicit evidence we have right now on what treating TRD [treatment-resistant depression] might look like with psilocybin.”

Levine also described a separate, small (19-participant), open-label study in which psilocybin was given as an adjunct to an existing SSRI. Although not powered for significance, the study signaled a robust response and remission, said Levine. He called these findings “unexpected” given that there had been preclinical evidence suggesting that chronic administration of serotonergic antidepressants downregulated the availability of

Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×

the 5-HT2A receptor as well as anecdotal reports that SSRI antidepressants interfered with the efficacy of psilocybin. Reiff commented that this study suggests that SSRI medication can be taken safely with psilocybin with minimal interference and that COMP360 psilocybin therapy can be taken as a monitored therapy or an adjunctive treatment to SSRI antidepressants.

Levine added that participants in both the 10- and 25-milligram dose groups reported psychedelic experiences. “Also, to some degree that happened with the 1-milligram group,” he said. More information on this aspect of the study will be published and presented at upcoming conferences, he said. Reiff suggested that the 1-milligram dose may be similar to what is referred to as a microdose,3 and could reflect a placebo effect.

Psilocybin Trials for Anxiety and Depression in Patients with Life-Threatening Illness

Patients with life-threatening illnesses, such as cancer, often develop depression and anxiety, which contributes to treatment non-adherence, prolonged hospitalization, increased suicidality, and an overall decreased quality of life (Griffiths et al., 2016). In a double-blind, randomized crossover study of patients with life-threatening cancer and a diagnosis of anxiety or mood disorder, Griffiths and colleagues showed that a high dose (22 or 30 mg) of psilocybin, but not a low dose (1 or 3 mg) (which served as an active control), produced significant decreases in depression and anxiety symptoms after 5 weeks, which persisted through the 6-month follow-up period. A similar double-blind, placebo-controlled randomized crossover study evaluated the efficacy of a single dose of psilocybin combined with psychotherapy in cancer patients with anxiety and depressive symptoms (Ross et al., 2016). This study also demonstrated significant and persistent reductions in all primary measures of depression and anxiety in the psilocybin group compared with the control group.

Psilocybin Trials for Substance Use Disorder

Clinical trials have also demonstrated the effectiveness of psilocybin for treating alcohol use disorder and promoting smoking abstinence, said Reiff. One study enrolled 10 participants who met the DSM-IV criteria for alcohol dependence and had at least 2 heavy drinking days in the previous 30 days. They received 14 sessions of psychotherapy that included motivation enhancement therapy and preparatory sessions, followed by

___________________

3 Microdosing with psychedelics was not a topic covered at this workshop. It has not been rigorously studied, according to Raison, nor is there a standard definition for a microdose, said Levine.

Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×

two psilocybin-assisted psychotherapy sessions and two debriefing sessions, said Reiff (Bogenschutz et al., 2015). The study demonstrated a significant and sustained increase in abstinence through 36 weeks and has prompted a much larger study by Michael Bogenschutz and his team at New York University that is currently ongoing, he said.

Another study of 15 participants who wanted to quit smoking combined a 15-week course that combined cognitive behavioral therapy with two or three psilocybin treatments, said Reiff (Johnson et al., 2017). At the 6-month follow-up, 80 percent of participants were laboratory verified as abstinent, he said.

Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×
Page 33
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×
Page 34
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×
Page 35
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×
Page 36
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×
Page 37
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×
Page 38
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×
Page 39
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×
Page 40
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×
Page 41
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×
Page 42
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×
Page 43
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×
Page 44
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×
Page 45
Suggested Citation:"4 Advancing Clinical Development: Challenges and Opportunities." National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. doi: 10.17226/26648.
×
Page 46
Next: 5 Anticipating Implementation to Guide Clinical Research and Development »
Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop Get This Book
×
Buy Paperback | $16.00 Buy Ebook | $12.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Psychiatric illnesses - such as major depressive disorder, anxiety disorder, substance use disorder, and posttraumatic stress disorder (PTSD) - are widely prevalent and represent a substantial health burden worldwide. Yet, conventional medications for mental illnesses often fail to provide relief to patients' disruptive and disabling symptoms. Existing and emerging evidence that psychedelics (e.g., LSD and psilocybin) and entactogens (e.g., MDMA) may be useful as tools to alleviate mental illness has sparked a renaissance of interest by investigators, clinicians, drug developers, and patient advocates in recent years. While promising data on therapeutic efficacy has energized research and development, resolving the mechanisms of action will be important for optimizing the efficacy and safety of these medicines. Further, evaluating the effect of psychedelics and entactogens on mood and behavior comes with unique challenges still in need of resolution. These include unresolved questions relating to blinding, placebo and nocebo effects, and the impact of psychosocial contexts.

In response to this renewed interest, the National Academies of Sciences, Engineering, and Medicine's Forum on Neuroscience and Nervous System Disorders convened a workshop on March 29-30, 2022. The workshop brought together a diverse group of stakeholders to explore the use of psychedelics and entactogens as treatments for psychiatric disorders. This Proceedings of a Workshop summarizes the presentations and discussions of the workshop.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!